Biocatalytic synthesis of chiral Duloxetine and its intermediate is one of the greatest technologies due to its high chemo-,regio- and stereo-selectivity;while the amount of available biocatalyst is yet limited and the conversion efficiency needs to be improved. In recent years,the availability of microbial genome sequences allows scientists to discover novel enzymes with potential applications. Based on the genome sequence of Candida parapsilosis,eight aldo-keto reductases were discovered and evaluated for the synthesis of N,N-dimethyl-3-keto-3-(2-thienyl)-1- propanamine (DKTP). Among them , CPAR4 showed higher catalytic ability for asymmetric reduction of N,N-dimethyl-3-keto-3-(2-thienyl)-1-propanamine (DKTP) to (S)-N,N-dimethyl-3-hydroxy-3-(2-thienyl)-1-propanamine (DHTP),a key intermediate of chiral Duloxetine. Then the biomediated reaction conditions using the cell-free system involving the expressed CPAR4 were optimized and (S)-DHTP (>99.9%ee) was produced with the yield of 94.5%at the initial substrate concentration of 3g/L,and even when the substrate concentration was increased to 5g/L,the enantiopure product can also be obtained with the yield over 70%. Therefore,the newly identified enzyme and its cell-free system would be promising for highly stereo specific bioreduction of prochiral pharmaceutical intermediates.%生物催化具有反应条件温和、绿色环保、高立体选择性等优点，已成为制备光学活性度洛西汀的重要方式和途径，但仍存在有效的生物催化剂数量有限和反应效率低等问题，基因组数据库的发展为新型立体选择性生物催化剂的开发提供了有效的途径和平台。本研究通过基因组信息挖掘，从 Candida parapsilosis CCTCCM 203011中发现了8个新型的醛酮还原酶，分析研究不同的醛酮还原酶对N,N-二甲基-3-酮-3-(2-噻吩)-1-丙胺(DKTP)的催化还原能力，发现 CPAR4能够高立体选择性地催化还原 DKTP 生成度洛西汀中间体(S)-N,N-二甲基-3-羟基-3-(2-噻吩)-1-丙胺(DHTP)。通过粗酶体系反应参数的优化，CPAR4催化还原底物浓度在3g/L 时，产率达到94.5%，光学纯度大于99.9%ee；当底物浓度为5g/L 时，产率仍达到70%以上。该重组菌粗酶液能够高立体选择性地生物还原DKTP生成度洛西汀中间体(S)-DHTP，具有一定的应用潜力。
展开▼
